Natural Capsules Limited · NSE:NATCAPSUQ
Natural Capsules — Q2 FY25 Earnings Presentation
33 slides from Natural Capsules's earnings presentation, Nov 13, 2024
Slide 1: Natural Capsules Limited Investor Presentation Cover Letter
NATURAL -, ARYS OSE C4, Iso Iso vee =o" ec &e Nd C A p S U L E S Io er Ls Eeey BE ee) E-) Pesaran . LIMITED Quality aL ELD & N EE ML Healing ie ee 2 saageuen rereus wewina™ 5 CORP & REGD OFFICE: “ TRIDENT TOWERS” No. 23, 4th Floor, 100 feet Road, Jayanagar 2nd Block, Bangalore-560011 Phone : 080-265
Slide 2: Investor Presentation November 2024
naturalcapsules.com investor Presentation NOVEMBER, 2024
Slide 3: Safe Harbor
Safe Harbor PRESENTATION Certain statements and opinions with respect to the anticipated future performance of Natural Capsules Limited (NCL) in the presentation (“forward - looking statements”), which reflect various assumptions concerning the strategies, objectives and anticipated results may or m
Slide 4: Inside this document
Inside this document PRESENTATION INVESTOR QUARTERLY COMPANY BUSINESS HIGHLIGHTS OVERVIEW CANVAS fa) jae FINANCIAL INVESTMENT ‘a = PERFORMANCE MERITS a a) jae — =) n a ed U — 4 ac =) ‘a < va
Slide 5: Quarterly Highlights
naturalcapsules.com Quarterly Highlights
Slide 6: Quarterly Updates — Q2FY25 (Consolidated)
Quarterly Updates — Q2FY25 (Consolidated) PRESENTATION REVENUES 41.22 cr EBITDA 4.50 cr ® 5.21% Q-0-Q ® 3.10%Q-0-Q INVESTOR ® 9.88% Y-o0-Y © -12.08% Y-o-Y EBITDA MARGINS 10.93% PAT (0.61) cr © -22 BPS Q-0-Q © -201.48% Q-0-Q © -273 BPS Y-o-Y © -139.27% Y-o-Y a lw ‘a = a 17a) lw EPS = (0.60) — =) 17a)
Slide 7: Management Commentary
Management Commentary PRESENTATION In Q2FY25, our capsules business demonstrated robust performance, with gross margins expanding due to a favourable product mix. Despite facing increased freight costs and a rise in other expenses, our EBITDA margins remained steady. We have INVESTOR ordered a new H
Slide 8: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement SummMary (consolidated) PRESENTATION PARTICULARS (z IN CRORES) Q2FY24 Q1FY24 evar. Q-0-Q Y-0o-Y H1FY24 Y-o-Y INVESTOR Revenue From Operations 37.52 39.18 41.22 5.21% 9.88% 75.21 80.41 6.91% Other Income 0.35 0.18 0.11 -41.16% -69.38% 0.52 0.29 -44.28% Total Income 37.86 39.36
Slide 9: Summary of Balance Sheet (Consolidated)
Summary of Balance Sheet (consolidated) PRESENTATION PARTICULARS (& IN CRORES) FY24 INVESTOR Total Equity 228.80 258.33 Non Current Liabilities 71.25 67.07 Current Liabilities 76.47 79.25 Total Equity and Liabilities 376.53 404.66 Non Current Assets 252.76 269.72 a jae} ‘a = a Current Assets 123.77
Slide 10: Summary of Cash Flow (Consolidated)
Summary of Cash Flow (consolidated) : a PARTICULARS (& IN CRORES) H1FY24 H1FY25 : Cash Flow From Operating Activities -15.32 12.01 : Cash Flow From Investing Activities -34.03 -20.18 Cash Flow From Financing Activities 49.06 15.36 Net Cash Flow -0.30 7.19 Cash At The Beginning Of The Period 1.48 2.2
Slide 11: Company Overview
naturalcapsules.com oyna) eye ahy Overview
Slide 12: Introducing Natural Capsules Limited (NCL)
Introducing Natural Capsules Limited (NCL) PRESENTATION Natural Capsules Limited (NCL) is a hard capsule shell manufacturer, who pioneered manufacturing of vegetarian capsules in India and is the second largest Indian manufacturer for gelatin capsules. The company was incorporated as a Public Limite
Slide 13: Our Journey
Our Journey PRESENTATION 1993- 2014: EARLY SUCCESSES AND A PERIOD OF EXPANSION INVESTOR CD ¢ NCL was CD ¢ Soon after, in CoD CD ¢ 2003 was an ° The coming CD * In 2005-2007, NCL Ce ° In 2009-2012, ED ° In 2012-14, NCL incorporated in 2001, NCL important decade witnessed acquired 5 lines NCL acquired
Slide 14: Our Journey: 2015 Onwards
2015 —- 2018: THE HURDLES WE GOING FORWARD FACED ON THE WAY Installed capacity as at Q4FY24 stands at 18.75 BCPA Fall in oil and commodity prices led to economic 2019 onward NCL witnessed an increase in slowdown in African countries and caused a decline in export of pharmaceutical products and deman
Slide 15: Product Offerings
Product Offerings PRESENTATION Natural Capsules Limited manufactures a vast array INVESTOR capsules, including vegetarian capsules which they have pioneered in India. The company is now foraying into API manufacturing with complex CAPSULES as high-end patented technology developed in-house, under it
Slide 16: Global Presence
Global Presence PRESENTATION Natural Capsules exports to 28 countries across 5 continents, bringing in sizable Ke\=A ULM ke Ane). 40le)a0 INVESTOR % OF EXPORT SALES AFRICA CIS Ghana * Georgia Tah} Oy Aey-) ieT a Nigeria Ca MacNN] South Africa ¢ Russian Federation Tunisia Uganda MIDDLE EAST 10.57% Zi
Slide 17: Serving Leading Brands
Serving Leading Brands PRESENTATION With over 3 decades of CUSTOMERS FOR REPEAT BUSINESS MORE THAN 10 YEARS DURING FY24 experience in the pharma INVESTOR sector, NCL has garnered 24% of total customers 89% of total turnover excellent relationship with customers across 28 countries. CUSTOMERS FOR MOR
Slide 18: Board of Directors
Board of Directors ya [e) ‘a ¢ ‘a z jae} Nn jae} a [a a [e) ‘a Nn jae} > z Mr. Laxminarayan Mundra Mr. Satyanarayana Mundra Mr. Sushil Kumar Mundra Mr. Sunil Mundra WHOLE TIME DIRECTOR WHOLE TIME DIRECTOR DIRECTOR MANAGING DIRECTOR (a) e ms = rf <x UO . ri Mr. Pramod Kasat Mr. T Y Prabhu Mr. S G Bel
Slide 19: Business Canvas
naturalcapsules.com see Canvas
Slide 20: Capsules Segment
Capsules Segment PRESENTATION With almost three decades of experience in the industry, Natural Capsules Limited is a leading manufacturer of hard capsules in India, its products are exported to regulated and unregulated markets across the globe, and largest INVESTOR following stringent applicable ru
Slide 21: Enhancing Capacities
Enhancing Capacities PRESENTATION Natural Capsules Limited has undergone recent CAPEX, to support its existing manufacturing capacity and to enable the company to capture market share in regulated markets. INVESTOR CAPSULES MANUFACTURING CAPACITY The ability to deliver faster = 38 Crores of capital
Slide 22: API Segment
API Segment : ra <x = Natural Capsules Limited is now foraying into the API business segment 2 through its subsidiary - Natural Biogenex Private Limited (NBPL) Greenfield Capex at a incorporated in 2020. The APIs that will be manufactured qumkur spread across ps acres bE are,Hydrocortisone, Predniso
Slide 23: API Segment contd.
API Segment conta) PRESENTATION THE FOLLOWING PRODUCTS AND CAPACITIES HAVE BEEN APPROVED UNDER THE PLI SCHEME DEXAMETHASONE INVESTOR 10 MT 24 MT ° NCL will be the only manufacturer of this product Planned Capacity Imports to India in FY24 in India worth ~ 2106 crores BETAMETHASONE 12 MT 45 MT ° NCL
Slide 24: Production Linked Incentive (PLI) Scheme
The scheme intends to boost domestic manufacturing x4 of identified KSMs, Drug Intermediates and APls by attracting large investments in the sector and thereby reduce India’s import dependence in critical APIs. With a view to attain self-reliance and reduce import A committee on drug security consti
Slide 25: Focus on R&D
Focus on R&D : Zz a = NCL strongly believes in investing in R&D, to stay ahead of its peers and to 2 consistently innovate. The Company's recent entry into the API business is 2 DSIR a art R&D facilities me R&D SPENDS & KEY AREAS OF RESEARCH 32 R&D AS A % OF REVENUE Team members focusing on product
Slide 26: Financial Performance
naturalcapsules.com y 4 A Financial a. or C —
Slide 27: Profit & Loss Statement Summary (Consolidated)
Profit & Loss Statement Summary (Consolidated) PRESENTATION PARTICULARS ¢ IN CRORES) FY20 FY21 FY22 FY23 FY24 INVESTOR Revenue from Operations 61.55 79.51 135.07 172.37 155.42 Other Income 0.95 0.73 1.01 0.57 1.94 Total Income 62.50 80.24 136.08 172.94 157.36 Total Operating Expenses 56.25 68.58 109
Slide 28: Balance Sheet Summary (Consolidated)
Balance Sheet Summary (Consolidated) PRESENTATION PARTICULARS ¢ IN CRORES) FY20 FY21 FY22 FY23 FY24 INVESTOR Total Equity (Networth) 55.62 62.10 82.98 148.25 228.80 Non-Current Liabilities 1.08 1.55 34.85 73.57 71.25 Current Liabilities 17.98 33.30 46.45 66.89 76.47 Total Equity and Liability 74.68
Slide 29: Cash Flow Statement Summary (Consolidated)
Cash Flow Statement Summary (Consolidated) PRESENTATION PARTICULARS ¢ IN CRORES) FY20 FY21 FY22 FY23 FY24 INVESTOR Cash Flow from Operating Activities 6.90 5.78 1.16 17.22 (8.35) Cash Flow from Investing Activities (5.74) (8.54) (45.88) (104.63) (72.59) Cash Flow from Financing Activities (1.18) 2.5
Slide 30: Investment Merits
naturalcapsules.com TiS deat Merits
Slide 31: Growth Drivers
Growth Drivers PRESENTATION dy ta u al v ea v v INVESTOR Capacity enhancement with Being the only backward Exploring opportunities The Company will benefit state-of-the-art machinery integrated manufacturer to set up capsules from strong industry tailwinds in capsules division, enabling of steroidal
Slide 32: Strategic Priorities
Strategic Priorities : e e e e Zz Xd : NCL is geared to bring about bP i monumental changes in its 7 With the ongoing CAPEX. the approach towards Its business. ! STRATEGIC PRIORITY > ACTIONS TAKEN ; e > Company is enabling itself to Positioning the business to red Collaboratina with b . | < . * Posi
Slide 33: Thank You
ii ( ) NATURAL naturalcapsules.com CAPSULES 308 Limitep Thank You CONTACT US FOR FURTHER INFORMATION, PLEASE CONTACT Natural Capsules Limited Mrs. Shilpa Burman Mr. Abhishek Mehra TRIDENT TOWERS, COMPANY SECRETARY INVESTOR RELATIONS ADVISOR Fourth Floor, No. 23, +91 95588 14500 100 Feet Road, Jaynag